Literature DB >> 12744857

CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation.

Joana G Brandão1, Rik J Scheper, Sinéad M Lougheed, David T Curiel, Bryan W Tillman, Winald R Gerritsen, Alfons J M van den Eertwegh, Herbert M Pinedo, Hidde J Haisma, Tanja D de Gruijl.   

Abstract

Adenoviral (Ad) transduction of dendritic cells (DC) is a promising vaccination strategy. However, clinical applicability of Ad vectors is hampered by the necessity to use high titers of infectious Ad particles for efficient DC transduction. Here, we report on the production of a bacterially expressed bispecific conjugate, consisting of a fusion of recombinant single-chain (sc) mAb Fv fragments, which bind and neutralize the Ad fiber knob (through the S11 mAb scFv) and retarget Ad to CD40 on the DC surface (through the G28-5 mAb scFv). We show that this bispecific scFv fusion protein significantly enhances transduction efficiency of monocyte-derived DC (MoDC), reduces the amount of virus needed for a given level of transduction, and increases the ability of MoDC to activate CTL in an antigen specific manner. This single-component conjugate may prove to be a valuable immunotherapeutic tool for the targeting of Ad to DC in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12744857     DOI: 10.1016/s0264-410x(03)00050-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Dendritic cell targeted vaccines: Recent progresses and challenges.

Authors:  Pengfei Chen; Xinsheng Liu; Yuefeng Sun; Peng Zhou; Yonglu Wang; Yongguang Zhang
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens.

Authors:  Casey A Maguire; Ramil Sapinoro; Natasha Girgis; Sol M Rodriguez-Colon; Servio H Ramirez; Jennifer Williams; Stephen Dewhurst
Journal:  Vaccine       Date:  2005-08-24       Impact factor: 3.641

3.  Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Ippei Shimomura; Shintaro Taki; Takeshi Nakanishi; Mitsuo Umetsu; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

4.  miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens.

Authors:  Matthias W Kron; Sigrid Espenlaub; Tatjana Engler; Reinhold Schirmbeck; Stefan Kochanek; Florian Kreppel
Journal:  Mol Ther       Date:  2011-05-10       Impact factor: 11.454

Review 5.  CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.

Authors:  Basav N Hangalapura; Laura Timares; Dinja Oosterhoff; Rik J Scheper; David T Curiel; Tanja D de Gruijl
Journal:  J Gene Med       Date:  2012-06       Impact factor: 4.565

Review 6.  Targeting human dendritic cells in situ to improve vaccines.

Authors:  Kartik Sehgal; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Immunol Lett       Date:  2014-07-27       Impact factor: 3.685

7.  Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.

Authors:  Briana Jill Williams; Shilpa Bhatia; Lisa K Adams; Susan Boling; Jennifer L Carroll; Xiao-Lin Li; Donna L Rogers; Nikolay Korokhov; Imre Kovesdi; Alexander V Pereboev; David T Curiel; J Michael Mathis
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

8.  Adenoviral transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantation.

Authors:  Oliver Treacy; Aideen E Ryan; Teresa Heinzl; Lisa O'Flynn; Marese Cregg; Mieszko Wilk; Francesca Odoardi; Paul Lohan; Timothy O'Brien; Mikhail Nosov; Thomas Ritter
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

Review 9.  Postexit surface engineering of retroviral/lentiviral vectors.

Authors:  Christoph Metzner; Feliks Kochan; John A Dangerfield
Journal:  Biomed Res Int       Date:  2013-04-17       Impact factor: 3.411

10.  A fusion protein between streptavidin and the endogenous TLR4 ligand EDA targets biotinylated antigens to dendritic cells and induces T cell responses in vivo.

Authors:  Laura Arribillaga; Maika Durantez; Teresa Lozano; Francesc Rudilla; Federico Rehberger; Noelia Casares; Lorea Villanueva; Marta Martinez; Marta Gorraiz; Francisco Borrás-Cuesta; Pablo Sarobe; Jesús Prieto; Juan José Lasarte
Journal:  Biomed Res Int       Date:  2013-09-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.